For each dosage group (15 micrograms and 30 micrograms), the investigators are seeking 60 volunteers who have CD4+ T-cell counts below 200, and 60 who have CD4+ T-cell counts equal to or greater than 200. The new study will analyze how CD4+ T-cell levels affect the response to the vaccine.

The trial is being conducted at six sites, including these five NIAID-funded Vaccine and Treatment Evaluation Units: Baylor College of Medicine, Houston; Cincinnati Children?s Hospital Medical Center; Saint Louis University, Mo.; University of Iowa, Iowa City; and University of Maryland, Baltimore. The University of Washington, Seattle, also is participating in the trial.

Additional details about this study are available at www.clinicaltrials

nih